New Distribution Model Drives Blockbuster Drug Access to the 'Last Mile': Baiair Medical Partners with Astellas Pharma

Highlights

Recently, Baheal Medical Inc., a pioneer in China’s new pharmaceutical distribution platform, has entered into a strategic retail market partnership with Astellas Pharma Inc., Japan’s second-largest prescription drug manufacturer. By joining forces with Baheal Medical, Astellas aims to accelerate the introduction of its tamsulosin hydrochloride sustained-release capsules (brand name: Harnal) into retail channels, thereby further expanding patient access to high-quality medications and improving the quality of life for a broad population of patients with benign prostatic hyperplasia (BPH).

As Japan’s second-largest prescription drug manufacturer, Astellas Pharma holds a leading position in the Japanese market in the fields of immunosuppressants for organ transplantation and urological therapies. Regarding this strategic cooperation with Baheal Medical, Astellas stated: “The momentum toward diversified development in China’s pharmaceutical market is currently strong. Through this strategic partnership with Qingdao Baheal Medical Inc., we aim to jointly build an innovative business model by leveraging Baheal’s professional digital marketing capabilities and robust marketing network platform. This collaboration seeks to meet the needs of numerous patients, ensure a stable supply of high-quality pharmaceutical products, and facilitate the delivery of high-value-added information, such as drug safety data. This strategic cooperation will drive further penetration into the retail terminal market and achieve omni-channel coverage for Astellas’ products. It represents a solid and crucial step in Astellas Pharma’s process of transforming its innovative scientific achievements into value for patients.”

Amid policy shifts and the evolution of China’s pharmaceutical retail market, traditional drug marketing models are no longer suited to the current business environment. Astellas further stated, “Baheal Medical’s new distribution platform, with its digital management capabilities and scenario-based solutions, can help us rapidly penetrate the retail market and deliver superior services and healthcare solutions to patients. Baheal has experienced rapid growth in recent years, and we are confident in this collaboration. More patients with medical needs will benefit from it.”

Baheal Medical stated, “Drawing on our understanding of medical practices and our extensive experience and capabilities cultivated over years in the healthcare sector, we aim to leverage Baheal’s innovative distribution model not only to ensure high-quality products reach end-users but also to facilitate their seamless integration into clinical settings for effective application, thereby benefiting a broad patient population. The future belongs to enterprises with professional expertise, superior quality, and technological sophistication. The collaboration between Baheal and Astellas holds significant promise. Moving forward, we will jointly provide robust support to more physicians and patients and contribute to advancing industry development.”